Now Is A Suitable Moment For A Long-Term Purchase Of Bristol-Myers Squibb Co. (NYSE: BMY)

Currently, there are 2.10B common shares owned by the public and among those 2.03B shares have been available to trade.

Insiders at the company have transacted a total of 136 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 85 of these insider trades were purchases, accounting for 708,048 shares. Insider sales of the common stock occurred on 51 occasions, with total insider shares sold totaling 423,399 shares.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


However, the script later moved the day high at 49.83, up 2.26%. The company’s stock has a 5-day price change of 2.26% and -4.98% over the past three months. BMY shares are trading -2.92% year to date (YTD), with the 12-month market performance down to -32.37% lower. It has a 12-month low price of $47.58 and touched a high of $73.84 over the same period. BMY has an average intraday trading volume of 0.99 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.62%, -1.16%, and -14.31% respectively.

Institutional ownership of Bristol-Myers Squibb Co. (NYSE: BMY) shares accounts for 78.75% of the company’s 2.10B shares outstanding.

It has a market capitalization of $101.35B and a beta (3y monthly) value of 0.37. The stock’s trailing 12-month PE ratio is 12.90, while the earnings-per-share (ttm) stands at $3.86. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.76% over the week and 2.07% over the month.

Analysts forecast that Bristol-Myers Squibb Co. (BMY) will achieve an EPS of $1.6 for the current quarter, $1.79 for the next quarter and $7.19 for 2025. The lowest estimate earnings-per-share for the quarter is $1.3 while analysts give the company a high EPS estimate of $1.94. Comparatively, EPS for the current quarter was $2.05 a year ago. Earnings per share for the fiscal year are expected to decrease by -8.64%, and 3.90% over the next financial year. EPS should shrink at an annualized rate of -2.63% over the next five years, compared to 5.13% over the past 5-year period.

Looking at the support for the BMY, a number of firms have released research notes about the stock. Redburn Atlantic stated their Neutral rating for the stock in a research note on February 06, 2024, with the firm’s price target at $77-$54.

Most Popular

Related Posts